Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Luigi Marchiori is active.

Publication


Featured researches published by Luigi Marchiori.


International Journal of Pancreatology | 1991

Antibacterial and mezlocillin-enhancing activity of pure human pancreatic fluid

Claudio Bassi; Roberta Fontana; Sergio Vesentini; G. Cavallini; Luigi Marchiori; Massimo Falconi; Stefano Corra; Paolo Pederzoli

SummaryThe majority of deaths in severe pancreatitis are the result of superinfection of necrotic tissue. The pathogen most commonly responsible for such infections isEscherichia coli. Antibiotic prophylaxis would appear a logical precaution. The antibacterial drugs of choice should possess two basic characteristics: they must be active against the flora responsible for the infections and must be capable of penetrating into the pancreas at adequate minimum inhibitory concentrations (MICs). Mezlocillin—which is active againstE. coli—has been shown to possess the latter requisite, but achieving therapeutic concentrations requires administration at high doses. In the present study, pure human pancreatic fluid showed properties similar to those observed in the dog againstE. coli (bacterial colony growth 100 times lower than in a control culture) and produced a 75 % reduction in mezlocillin MICs against this organism. These enhancing characteristics might make the commonly used doses sufficient for prophylactic purposes.


Tumori | 1989

Serum copper and ceruloplasmin in early and in advanced hepatocellular carcinoma: diagnostic and prognostic relevance.

Massimo Casaril; Franco Capra; Luigi Marchiori; Giovanni Battista Gabrielli; Nicola Nicoli; Flavia Corso; Fiorenza Baracchino; Roberto Corrocher

To evaluate the prognostic value of serum copper (S-Cu) and ceruloplasmin and their pathophysiologic significance in human hepatocellular carcinoma (HCC), we studied 49 patients with HCC (20 of which were submitted to partial hepatectomy) compared with 110 patients with liver cirrhosis. In HCC both S-Cu and ceruloplasmin were higher than in cirrhosis; moreover, S-Cu was correlated with the extension of HCC, evaluated by instrumental data and by surgical inspection. In cirrhotic patients, mean S-Cu was 122.9 μg/dl (SD, 29.3), in early HCC, 153.0 μg/dl (SD, 34.5), and in advanced HCC, 193.1 μg/dl (SD, 37.7). Variance analysis gave F = 59.4. In HCC patients S-Cu was positively correlated with ceruloplasmin and with fibrinogen. Survival, evaluated by Mantels test stratified for surgical therapy, was longer in patients with S-Cu levels lower than 175 μg/dl and in those at an earlier stage. We therefore conclude that S-Cu has a relevant diagnostic value in detecting HCC also in early stage and allows prognostic evaluation as regards survival.


Digestive Diseases and Sciences | 2003

Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors.

Franco Capra; Elena De Maria; Massimo Franchini; Luigi Marchiori; Ulrich Thalheimer; Italo Vantini

At present two of the most relevant problems of the therapy of HCV-related chronic active hepatitis are the retreatment of nonresponders to interferon-α (IFN-α) and the definition of a prognostic index of response. We treated 44 patients who previously were nonresponders to IFN-α alone with IFN-α plus ribavirin for 12 months. Among the tests performed, we included the serum level of soluble intercellular adhesion molecule-1 (sICAM-1) at the beginning of the trial and at 3 months thereafter. We obtained 56.81% end of treatment responses and 47.72% sustained responses. A decrease of at least 10% of the sICAM-1 serum level during the first 3 months of treatment strongly correlated to the results of therapy while the usual important prognostic factors (HCV genotype and viral load) did not show this relation.


American Journal of Surgery | 2004

A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation

Nicola Nicoli; Andrea Casaril; Moh'd Abu Hilal; Gerardo Mangiante; Luigi Marchiori; Michele Ciola; Laura Invernizzi; Tommaso Campagnaro; Giancarlo Mansueto


Journal of Hepato-biliary-pancreatic Surgery | 2001

Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation

Nicola Nicoli; Andrea Casaril; Luigi Marchiori; Gerardo Mangiante; Alì Reza Hasheminia


The Journal of Infectious Diseases | 2000

Serum Level of Soluble Intercellular Adhesion Molecule 1 in Patients with Chronic Liver Disease Related to Hepatitis C Virus: A Prognostic Marker for Responses to Interferon Treatment

Franco Capra; Elena De Maria; Claudio Lunardi; Luigi Marchiori; Paolo Mezzelani; Ruggero Beri; Giovanni Battista Gabrielli


Hepato-gastroenterology | 2004

Surgical treatment for liver metastases from colorectal carcinoma: results of 228 patients

Nicola Nicoli; Andrea Casaril; Gerardo Mangiante; Michele Ciola; Moh'd Abu Hilal; Luigi Marchiori


Journal of Surgical Oncology | 1993

Treatment of hepatocellular carcinoma

Nicola Nicoli; Luigi Marchiori; Gian Carlo Mansueto; Gianni Morana; Anna Bellini; Francesco G. Musajo; Luca Bortolasi; Ivano Dal Dosso; Vinicio Costa; Paolo Pederzoli; Sergio Vesentini


Tumori | 2002

Complications after Radiofrequency Thermal Ablation for Liver Malignancies

Andrea Casaril; Luigi Marchiori; Gerardo Mangiante; Michele Ciola; Nicola Nicoli


Tumori | 2002

Report of a Case of Rapid Intrahepatic Spreading of Hcc after Radiofrequency Thermal Ablation

Andrea Casaril; Luigi Marchiori; Gerardo Mangiante; Michele Ciola; Nicola Nicoli

Collaboration


Dive into the Luigi Marchiori's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge